Efficacy of Diet on Quality of Life in Multiple Sclerosis

NCT ID: NCT05007483

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-10

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio and the highest incidence rates among whites and African Americans. The economic cost of managing MS is substantial. In the U.S., the total medical costs for patients with MS increased from $116 million in 2002 to $198 million in 2013. MS is a chronic, neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the ability to maintain employment.

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

The proposed study will consist of study participants attending 3 in-person site visits, months 0, 3, and 24, and online surveys every 3 months (months 0-24).

This study will use a randomized single-blind controlled design to test the short-term (6 months) and long-term (an additional 18 months) impact of the intervention diets on symptoms of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in period to identify participants who are most likely to be successful in completing study procedures; this process has been effective in our previous studies. Participants who successfully complete all baseline self-reported outcomes and follow all study procedures during the seven-day run-in period will be scheduled for an on-site baseline visit for randomization to one of three diets (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination and Dietary Guidelines for America).

On-site study visits will include blood draws, motor, cognitive, vision function assessments, and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole pegboard to test hand function, symbol digit exercise to test thinking functions, and critical flicker fusion test, ocular coherence tomography and low contrast vision sensitivity to test vision. The study participant will be escorted to the MRI unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be randomized. Participants assigned to the intervention diets will be given intervention specific educational materials including shopping lists, example menus and recipes, and the study supplements. Study participants randomized to the dietary guidelines for Americans diet will receive emails and/or text messages (approximately 3-6 weeks) to receive resources with websites for the Dietary Guidelines of America, and recent multiple sclerosis-related research that does not involve diet.

Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two intervention groups only. The participant will be scheduled for a Zoom video conference meeting with the assigned registered dietitian to review the assigned study diet.

In addition, subjects will collect saliva specimens for microbiome analysis at each of the 3 site study visits (months 0, 3 and 24).

Dietary History Questionnaire III will be completed at months 0, 3, 12 and 24 and will be used to assess adherence to the assigned dietary pattern.

The online questionnaires sent to participants every 3 months will also be used to track supplement intake, medication use, and details about health \& life events, MS symptoms, fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled study design
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
Assessors and principle investigator masked

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (Modified paleolithic elimination diet).

Modified paleolithic elimination diet.

Group Type EXPERIMENTAL

BodyBio Balance Oil

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

Kirunal Fish Oil

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

BodyBio PC

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

Modified Paleolithic Elimination diet

Intervention Type BEHAVIORAL

1. Complete elimination of all gluten-, dairy-, and egg-containing foods.
2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.
3. Consume 6-12 ounces/day protein including organ meats and fatty fish.
4. Consume fermented foods daily.
5. Consume daily servings of algae, seaweed, and nutritional yeast.

Group 2 (TROO)

Time Restricted Olive Oil Based (TROO) Ketogenic Diet

Group Type EXPERIMENTAL

BodyBio Balance Oil

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

Kirunal Fish Oil

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

BodyBio PC

Intervention Type DIETARY_SUPPLEMENT

nutraceutical supplement

Time Restricted Olive Oil Based (TROO) Ketogenic Diet

Intervention Type BEHAVIORAL

1. Restriction of dietary carbohydrates to \< 50 grams/day.
2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.
3. Consume \<100 grams/day protein.
4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).
5. Consume at least 3 servings/day non-starchy vegetables.

Group 3 Control

Usual diet with Dietary Guidelines for Americans Diet information

Group Type ACTIVE_COMPARATOR

Usual diet with Dietary Guidelines for Americans Diet information

Intervention Type BEHAVIORAL

1. Limit sodium to \< 2,300 mg/day.
2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.
3. Consume 5 servings of fruits and vegetables per day.
4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.
5. Consume 3 servings of reduced fat dairy per day.
6. Consume 6 ounces/day protein foods.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BodyBio Balance Oil

nutraceutical supplement

Intervention Type DIETARY_SUPPLEMENT

Kirunal Fish Oil

nutraceutical supplement

Intervention Type DIETARY_SUPPLEMENT

BodyBio PC

nutraceutical supplement

Intervention Type DIETARY_SUPPLEMENT

Modified Paleolithic Elimination diet

1. Complete elimination of all gluten-, dairy-, and egg-containing foods.
2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.
3. Consume 6-12 ounces/day protein including organ meats and fatty fish.
4. Consume fermented foods daily.
5. Consume daily servings of algae, seaweed, and nutritional yeast.

Intervention Type BEHAVIORAL

Time Restricted Olive Oil Based (TROO) Ketogenic Diet

1. Restriction of dietary carbohydrates to \< 50 grams/day.
2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.
3. Consume \<100 grams/day protein.
4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).
5. Consume at least 3 servings/day non-starchy vegetables.

Intervention Type BEHAVIORAL

Usual diet with Dietary Guidelines for Americans Diet information

1. Limit sodium to \< 2,300 mg/day.
2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.
3. Consume 5 servings of fruits and vegetables per day.
4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.
5. Consume 3 servings of reduced fat dairy per day.
6. Consume 6 ounces/day protein foods.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1400 mg linoleic acid/350 mg linolenic acid 315 mg eicosapentanoic acid/ 105 mg docosahexaenoic acid 1300 mg phosphatidylcholine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A definitive diagnosis of RRMS based on the 2017 revised McDonald Criteria.
* The ability to prepare, or availability of someone to prepare, home-cooked meals.
* Must own a computer, smartphone, or tablet device that has internet access to complete online surveys and capable of running study related applications.
* Must be willing to follow study procedures outlined and explained to them.
* Be between the ages of 18 to 70 at the time of consent.
* Must be able to walk 25 feet without support.
* Willingness to be randomized and follow any of the study diets.
* Must consent to sharing the clinical notes from their primary care and neurology providers during the study period.

Exclusion Criteria

* Moderate or severe mental impairment.
* Use of insulin, Coumadin, weight loss medications such as orlistat that causes fat malabsorption.
* Worsening of symptoms resulting in the initiation or change of treatment including steroids (solumedrol, prednisone, etc.) or disease-modifying medications in 4 weeks prior to consent.
* Treatment for cancer by radiation or chemotherapy in 12 months prior to consent, other than skin cancer.
* Diagnosis of clinically significant heart disease, liver disease, kidney disease, or history of oxalate kidney stones.
* Diagnosis of type II diabetes that does not have approval from treating physicians to adopt any of the 3 study diets.
* Clinical diagnosis of moderate to severe psychiatric disease that makes study adherence more difficult (e.g., schizophrenia, bi-polar disease, severe depression and/or anxiety).
* An active eating disorder such as anorexia, bulimia, binge eating, or orthorexia.
* Measurement of BMI \<20.
* Confirmation of pregnancy or planning to become pregnant in the next 2 years.
* History of diagnosed fat intolerance/malabsorption such as cholecystectomy or uncontrolled exocrine pancreatic insufficiency.
* Participation in another research study investigating MS treatments, diet, or exercise.
* Presence of a contraindication to completing a brain MRI or having claustrophobia which interferes with completion of MRI studies without the use of sedation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Terry L. Wahls

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Terry L. Wahls

Principle Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Terry L Wahls, MD

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univeristy of Iowa

Iowa City, Iowa, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Wahls TL, Chenard CA, Snetselaar LG. Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic. Nutrients. 2019 Feb 7;11(2):352. doi: 10.3390/nu11020352.

Reference Type RESULT
PMID: 30736445 (View on PubMed)

Wahls T, Scott MO, Alshare Z, Rubenstein L, Darling W, Carr L, Smith K, Chenard CA, LaRocca N, Snetselaar L. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials. 2018 Jun 4;19(1):309. doi: 10.1186/s13063-018-2680-x.

Reference Type RESULT
PMID: 29866196 (View on PubMed)

Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between a Modified Paleolithic Diet for Multiple Sclerosis and the Recommended Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 1;11(3):537. doi: 10.3390/nu11030537.

Reference Type RESULT
PMID: 30832289 (View on PubMed)

Titcomb TJ, Bisht B, Moore DD 3rd, Chhonker YS, Murry DJ, Snetselaar LG, Wahls TL. Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet. Nutrients. 2020 Jun 20;12(6):1844. doi: 10.3390/nu12061844.

Reference Type RESULT
PMID: 32575774 (View on PubMed)

Lee JE, Bisht B, Hall MJ, Rubenstein LM, Louison R, Klein DT, Wahls TL. A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis. J Am Coll Nutr. 2017 Mar-Apr;36(3):150-168. doi: 10.1080/07315724.2016.1255160. Epub 2017 Apr 10.

Reference Type RESULT
PMID: 28394724 (View on PubMed)

Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma beta-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988. Epub 2020 Mar 26.

Reference Type RESULT
PMID: 32213121 (View on PubMed)

Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between the Low Saturated Fat Swank Diet for Multiple Sclerosis and Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 13;11(3):616. doi: 10.3390/nu11030616.

Reference Type RESULT
PMID: 30871265 (View on PubMed)

Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949. eCollection 2017.

Reference Type RESULT
PMID: 30050374 (View on PubMed)

Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.

Reference Type RESULT
PMID: 24476345 (View on PubMed)

Shemirani F, Klein AM, Groux AR, Kilpatrick R, Brooks L, Ehlinger MA, Darling WG, Magnotta VA, Gill CM, Hoth KF, Mangalam A, Eyck PT, Martinez AS, Hook J, Titcomb TJ, Snetselaar LG, Wahls TL. Efficacy of Diet on Quality of life in Multiple Sclerosis (EDQ-MS): a study protocol for a randomized controlled clinical trial. Trials. 2025 Oct 27;26(1):437. doi: 10.1186/s13063-025-09157-2.

Reference Type DERIVED
PMID: 41146285 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202104639

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of DHA in Patients With Multiple Sclerosis
NCT07346703 ENROLLING_BY_INVITATION NA